07-06-2025
Alvotech and Dr. Reddy’s to co-develop biosimilar candidate to Keytruda® (pembrolizumab)
Alvotech and Dr. Reddy’s to co-develop biosimilar candidate to Keytruda® (pembrolizumab)
News
Read More
06-02-2025
Dr. Reddy’s enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex & Darzalex Faspro in the U.S., and Europe
Read More
08-12-2024
Dr. Reddy's receives positive CHMP opinion from EMA for its proposed Rituximab biosimilar
Read More
28-11-2024
Dr Reddy's launches novel cancer therapy Toripalimab in India
Read More
29-07-2024
Dr. Reddy's rituximab biosimilar ituxredi gets EMA CHMP positive recommendation
Read More
29-07-2024
Dr Reddy’s gets positive opinion from EMA for its rituximab biosimilar
Read More
29-07-2024
Dr. Reddy’s biosimilar gets recommendation from European Medicines Agency
Read More
29-06-2024
Zydus and Dr Reddy's ink licensing agreement to co-market Pertuzumab in India.
Read More
28-06-2024
Pertuzumab is a biosimilar medicine from Dr. Reddy's
Read More
28-06-2024
Zydus Life, Dr Reddy's partner to co-market Pertuzumab biosimilar for breast cancer treatment
Read More
Sidharth B
Product Dev.
R. Anitha
Quality
Gajanan Rathod
Digital
Prabhu
Quality
Vishnu Chandran
Reg. Affairs
Bricks of Biologics, appreciates the contribution and celebrates our people who are the building blocks of Dr. Reddy's Biologics.
Bricks of biologics in general refers to bio-bricks as genetic building blocks which are DNA sequences that can be assembled to create complex biological systems.